Compare Teradyne, Inc. (TER) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Teradyne, Inc. trades at $349.85 (market cap $59.45B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Teradyne, Inc. is far larger — about 12.2× Travere Therapeutics Inc. Common Stock's market cap, and Teradyne, Inc. pays a 0.14% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TER | TVTX | |
|---|---|---|
Market Cap | $59.45B | $4.88B |
Volume | 2,735,541 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $483.84 | $67.52 |
52-Week Low | $138.09 | $26.79 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $59.20B | $5.01B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $359.44, down 6.36% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a 25.77% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, targeting growth in semiconductor and data center markets. Analyst consensus remains bullish with a $461.50 price target, though technical indicators suggest near-term caution.
Outlook is positive due to robust profitability and AI-related demand, but risks include competitive pressures and market volatility. The stock offers growth potential if execution aligns with analyst expectations, though investors should monitor earnings consistency and industry trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
